AGIO
Agios Pharmaceuticals Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 02-14-2019 | 11-01-2018 | 08-02-2018 | 05-04-2018 | 02-14-2018 | 11-01-2017 | 08-08-2017 | 05-04-2017 | |
|---|---|---|---|---|---|---|---|---|
| Actual EPS | -1.58 | -1.63 | -1.19 | -1.63 | -1.81 | -1.59 | -1.78 | -1.56 |
| Consensus EPS | -1.65 | -1.69 | -1.62 | -1.6 | -1.65 | -1.74 | -1.52 | -1.79 |
| Estimated EPS | -1.65 | -1.69 | -1.62 | -1.6 | -1.65 | -1.74 | -1.52 | -1.79 |
| Number of Estimates | 6 | 6 | 5 | 4 | 5 | 5 | 6 | 6 |
| EPS Surprise | $0.07 | $0.06 | $0.43 | -$0.03 | -$0.16 | $0.15 | -$0.26 | $0.23 |
Stats
Summary
Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
Market Cap: 4.5 Billion
Primary Exchange: Nasdaq Global Select
Website: http://www.agios.com
Shares Outstanding: 55.7 Million
Float: 55 Million
Dividend: 0.0 (0.0%)
Beta: 2.237777
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 6.72 Million
Ethical Flags
Longest drawdown: 1109 trading days
From: 2015-01-14 To: 2019-06-12
Lowest Point:
Key events next week - healthcare
via: SeekingAlpha at 2019-06-13 03:28:10:000
Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more … read more...
Week In Review: WuXi Biologics Signs LOI For $3 Billion Vaccine Contract
via: SeekingAlpha at 2019-05-26 09:31:53:000
Deals and Financings WuXi Biologics (HK: 2269) has entered into a Letter of Intent with an unnamed vaccine company to form a strategic partnership calling for WuXi Vaccines to build a dedicated manufacturing facility that will supply the partner's vaccines for global markets. WuXi Vaccines… read more...
Week In Review: WuXi Biologics Signs LOI For $3 Billion Vaccine Contract
via: SeekingAlpha at 2019-05-26 09:31:53:000
Deals and Financings WuXi Biologics (HK: 2269) has entered into a Letter of Intent with an unnamed vaccine company to form a strategic partnership calling for WuXi Vaccines to build a dedicated manufacturing facility that will supply the partner's vaccines for global markets. WuXi Vaccines… read more...
Week In Review: WuXi Biologics Signs LOI For $3 Billion Vaccine Contract
via: SeekingAlpha at 2019-05-26 09:31:53:000
Deals and Financings WuXi Biologics (HK: 2269) has entered into a Letter of Intent with an unnamed vaccine company to form a strategic partnership calling for WuXi Vaccines to build a dedicated manufacturing facility that will supply the partner's vaccines for global markets. WuXi Vaccines… read more...
Week In Review: WuXi Biologics Signs LOI For $3 Billion Vaccine Contract
via: SeekingAlpha at 2019-05-26 09:31:53:000
Deals and Financings WuXi Biologics (HK: 2269) has entered into a Letter of Intent with an unnamed vaccine company to form a strategic partnership calling for WuXi Vaccines to build a dedicated manufacturing facility that will supply the partner's vaccines for global markets. WuXi Vaccines… read more...
GEVO, TRQ among premarket gainers
via: SeekingAlpha at 2019-05-16 05:21:37:000
Iovance Biotherapeutics (NASDAQ: IOVA ) +36% on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more … read more...
GEVO, TRQ among premarket gainers
via: SeekingAlpha at 2019-05-16 05:21:37:000
Iovance Biotherapeutics (NASDAQ: IOVA ) +36% on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more … read more...
GEVO, TRQ among premarket gainers
via: SeekingAlpha at 2019-05-16 05:21:37:000
Iovance Biotherapeutics (NASDAQ: IOVA ) +36% on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more … read more...
Agios' ivosidenib successful in late-stage cholangiocarcinoma study
via: SeekingAlpha at 2019-05-15 12:12:40:000
A Phase 3 clinical trial, ClarIDHy , evaluating Agios Pharmaceuticals' (NASDAQ: AGIO ) TIBSOVO (ivosidenib) in previously treated patients with IDH1 mutation-positive cholangiocarcinoma met the primary endpoint of progression-free survival (PFS) compared to placebo. More news on: Agios … read more...
Ideaya IPO: At An Early Stage Of Development, But Google Is A Shareholder
via: SeekingAlpha at 2019-05-10 14:59:00:000
With Google Ventures ( GOOG ) (GOOLG) and Celgene ( CELG ) behind Ideaya Biosciences ( IDYA ), the company will be followed closely by the market. The most favorable is that the companys portfolio includes more than six biomarkers, which should permit the company to target a signific… read more...
Ideaya IPO: At An Early Stage Of Development, But Google Is A Shareholder
via: SeekingAlpha at 2019-05-10 14:59:00:000
With Google Ventures ( GOOG ) (GOOLG) and Celgene ( CELG ) behind Ideaya Biosciences ( IDYA ), the company will be followed closely by the market. The most favorable is that the companys portfolio includes more than six biomarkers, which should permit the company to target a signific… read more...
Ideaya IPO: At An Early Stage Of Development, But Google Is A Shareholder
via: SeekingAlpha at 2019-05-10 14:59:00:000
With Google Ventures ( GOOG ) (GOOLG) and Celgene ( CELG ) behind Ideaya Biosciences ( IDYA ), the company will be followed closely by the market. The most favorable is that the companys portfolio includes more than six biomarkers, which should permit the company to target a signific… read more...
Ideaya IPO: At An Early Stage Of Development, But Google Is A Shareholder
via: SeekingAlpha at 2019-05-10 14:59:00:000
With Google Ventures ( GOOG ) (GOOLG) and Celgene ( CELG ) behind Ideaya Biosciences ( IDYA ), the company will be followed closely by the market. The most favorable is that the companys portfolio includes more than six biomarkers, which should permit the company to target a signific… read more...
Ideaya IPO: At An Early Stage Of Development, But Google Is A Shareholder
via: SeekingAlpha at 2019-05-10 14:59:00:000
With Google Ventures ( GOOG ) (GOOLG) and Celgene ( CELG ) behind Ideaya Biosciences ( IDYA ), the company will be followed closely by the market. The most favorable is that the companys portfolio includes more than six biomarkers, which should permit the company to target a signific… read more...
Agios: Expanded FDA Approval Of Tibsovo Will Lead To Other Opportunities
via: SeekingAlpha at 2019-05-08 19:07:34:000
Agios Pharmaceuticals ( AGIO ) announced FDA approval for its supplemental new drug application (sNDA) for TIBSOVO to treat newly diagnosed adult acute myeloid leukemia ((AML)) patients who have the IDH1 mutation and are ineligible for intensive chemotherapy. This newly expanded label wi… read more...
Agios: Expanded FDA Approval Of Tibsovo Will Lead To Other Opportunities
via: SeekingAlpha at 2019-05-08 19:07:34:000
Agios Pharmaceuticals ( AGIO ) announced FDA approval for its supplemental new drug application (sNDA) for TIBSOVO to treat newly diagnosed adult acute myeloid leukemia ((AML)) patients who have the IDH1 mutation and are ineligible for intensive chemotherapy. This newly expanded label wi… read more...
Agios: Expanded FDA Approval Of Tibsovo Will Lead To Other Opportunities
via: SeekingAlpha at 2019-05-08 19:07:34:000
Agios Pharmaceuticals ( AGIO ) announced FDA approval for its supplemental new drug application (sNDA) for TIBSOVO to treat newly diagnosed adult acute myeloid leukemia ((AML)) patients who have the IDH1 mutation and are ineligible for intensive chemotherapy. This newly expanded label wi… read more...
Biotech News Recap: Biogen Reports Promising Data In ALS, Still Facing Several Challenges
via: SeekingAlpha at 2019-05-05 12:29:00:000
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and … read more...
Biotech News Recap: Biogen Reports Promising Data In ALS, Still Facing Several Challenges
via: SeekingAlpha at 2019-05-05 12:29:00:000
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and … read more...
Biotech News Recap: Biogen Reports Promising Data In ALS, Still Facing Several Challenges
via: SeekingAlpha at 2019-05-05 12:29:00:000
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and … read more...
IDEAYA Biosciences Files For U.S. IPO
via: SeekingAlpha at 2019-05-03 12:30:36:000
Quick Take IDEAYA Biosciences ( IDYA ) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the discovery and development of cancer therapeutics. IDYA is in Phase 1/2 trials (run by Novartis) for its lead c… read more...
IDEAYA Biosciences Files For U.S. IPO
via: SeekingAlpha at 2019-05-03 12:30:36:000
Quick Take IDEAYA Biosciences ( IDYA ) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the discovery and development of cancer therapeutics. IDYA is in Phase 1/2 trials (run by Novartis) for its lead c… read more...
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-02 10:40:13:000
Agios Pharmaceuticals, Inc. (AGIO) Q1 2019 Results Earnings Conference Call May 02, 2019, 08:00 AM ET Company Participants Kendra Adams - Vice President, Investor Relations Jackie Fouse - Chief Executive Officer Chris Bowden - Chief Medical Officer Andrew Hirsch - Chief Financi… read more...
Agios Pharmaceuticals, Inc. 2019 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-05-02 06:18:31:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more … read more...
Agios reports Q1 Tibsovo sales of $9.1M
via: SeekingAlpha at 2019-05-02 04:55:41:000
Agios Pharmaceuticals ( AGIO ) Q1 results : Revenues: $30.2M (+243.2%); Tibsovo Sales: $9.1M; Party related collaboration revenue: $17.9M (+145.2%); Royalty revenue: $2.2M (+57.1%). More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read m… read more...
Agios Pharmaceuticals beats by $0.16, beats on revenue
via: SeekingAlpha at 2019-05-02 03:06:41:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q1 GAAP EPS of -$1.59 beats by $0.16 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Apple Makes Its Video-Streaming Move (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-03-24 04:10:31:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...
Apple Makes Its Video-Streaming Move (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-03-24 04:10:31:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...
Apple Makes Its Video-Streaming Move (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-03-24 04:10:31:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...
Stocks To Watch: Apple Makes Its Video-Streaming Move
via: SeekingAlpha at 2019-03-23 05:05:44:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The increasingly hot market for online video delivery is set to take another sharp … read more...
Agios up 5% on new ivosidenib data
via: SeekingAlpha at 2019-02-25 09:57:30:000
Agios Pharmaceuticals ( AGIO +5% ) is up on light volume in early trade in response to updated data from a Phase 1 clinical trial evaluating TIBSOVO (ivosidenib), combined with Celgene's ( CELG +0.8% ) VIDAZA (azacitidine), for the first-line treatment of patients with IDH1 mutation-po… read more...
Agios up 5% on new ivosidenib data
via: SeekingAlpha at 2019-02-25 09:57:30:000
Agios Pharmaceuticals ( AGIO +5% ) is up on light volume in early trade in response to updated data from a Phase 1 clinical trial evaluating TIBSOVO (ivosidenib), combined with Celgene's ( CELG +0.8% ) VIDAZA (azacitidine), for the first-line treatment of patients with IDH1 mutation-po… read more...
Agios up 5% on new ivosidenib data
via: SeekingAlpha at 2019-02-25 09:57:30:000
Agios Pharmaceuticals ( AGIO +5% ) is up on light volume in early trade in response to updated data from a Phase 1 clinical trial evaluating TIBSOVO (ivosidenib), combined with Celgene's ( CELG +0.8% ) VIDAZA (azacitidine), for the first-line treatment of patients with IDH1 mutation-po… read more...
Jefferies sees 46% upside in CareDx in premarket analyst action
via: SeekingAlpha at 2019-02-15 07:46:21:000
CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more … read more...
Jefferies sees 46% upside in CareDx in premarket analyst action
via: SeekingAlpha at 2019-02-15 07:46:21:000
CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more … read more...
Jefferies sees 46% upside in CareDx in premarket analyst action
via: SeekingAlpha at 2019-02-15 07:46:21:000
CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more … read more...
Jefferies sees 46% upside in CareDx in premarket analyst action
via: SeekingAlpha at 2019-02-15 07:46:21:000
CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more … read more...
Jefferies sees 46% upside in CareDx in premarket analyst action
via: SeekingAlpha at 2019-02-15 07:46:21:000
CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more … read more...
Jefferies sees 46% upside in CareDx in premarket analyst action
via: SeekingAlpha at 2019-02-15 07:46:21:000
CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more … read more...
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-14 13:04:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2018 Results Earnings Conference Call February 14, 2019, 08:00 AM ET Company Participants Kendra Adams - Senior Director, Investor & Public Relations Jackie Fouse - Chief Executive Officer Chris Bowden - Chief Medical Officer Steve Hoer… read more...
Agios Pharmaceuticals, Inc. 2018 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-02-14 10:55:53:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more … read more...
Agios Pharma Q4 top line up 206%
via: SeekingAlpha at 2019-02-14 10:13:45:000
Agios Pharmaceuticals ( AGIO +8.2% ) Q4 results : Revenues: $30M (+206.1%); Product revenue: $9.4M; Party related collaboration revenue: $18.2M (+111.6%); Royalty revenue: $2.2M (+83.3%). More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary … read more...
Agios Pharmaceuticals beats by $0.07, beats on revenue
via: SeekingAlpha at 2019-02-14 07:06:41:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 GAAP EPS of -$1.58 beats by $0.07 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2019-02-13 17:30:30:000
AAN , AEE , AER , AGIO , ALE , ALKS , ARCH , AVP , AZN , BAM , BCOR , BGCP , BLMN , BWA , CBB , CCEP , CME , COWN , CYBR , DGX , DNOW , DUK , EEX , EPAM , EQM , EQT , FAF , GEO , GLOG , GNRC , GOOS , GTLS , HII , HPP , INCY , IQV , IRM , KO , LECO , M… read more...
Agios Pharmaceuticals (AGIO) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-09 13:25:15:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals (AGIO) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-09 13:25:15:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals (AGIO) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-09 13:25:15:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Questioning Agios Pharmaceuticals' Future Revenue
via: SeekingAlpha at 2018-12-07 15:09:29:000
Agios Pharmaceuticals ( AGIO ) had been one of the bright spots in the small-cap pharmaceutical or biotechnology space earlier in 2018. On December 4, 2018, it closed at $54.05, down 46% from its 52-week high of $99.82. With its first two drugs approval occurring during the past year, you woul… read more...
Questioning Agios Pharmaceuticals' Future Revenue
via: SeekingAlpha at 2018-12-07 15:09:29:000
Agios Pharmaceuticals ( AGIO ) had been one of the bright spots in the small-cap pharmaceutical or biotechnology space earlier in 2018. On December 4, 2018, it closed at $54.05, down 46% from its 52-week high of $99.82. With its first two drugs approval occurring during the past year, you woul… read more...
Questioning Agios Pharmaceuticals' Future Revenue
via: SeekingAlpha at 2018-12-07 15:09:29:000
Agios Pharmaceuticals ( AGIO ) had been one of the bright spots in the small-cap pharmaceutical or biotechnology space earlier in 2018. On December 4, 2018, it closed at $54.05, down 46% from its 52-week high of $99.82. With its first two drugs approval occurring during the past year, you woul… read more...
Questioning Agios Pharmaceuticals' Future Revenue
via: SeekingAlpha at 2018-12-07 15:09:29:000
Agios Pharmaceuticals ( AGIO ) had been one of the bright spots in the small-cap pharmaceutical or biotechnology space earlier in 2018. On December 4, 2018, it closed at $54.05, down 46% from its 52-week high of $99.82. With its first two drugs approval occurring during the past year, you woul… read more...
Questioning Agios Pharmaceuticals' Future Revenue
via: SeekingAlpha at 2018-12-07 15:09:29:000
Agios Pharmaceuticals ( AGIO ) had been one of the bright spots in the small-cap pharmaceutical or biotechnology space earlier in 2018. On December 4, 2018, it closed at $54.05, down 46% from its 52-week high of $99.82. With its first two drugs approval occurring during the past year, you woul… read more...
Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia
via: SeekingAlpha at 2018-11-27 08:00:00:000
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients … read more...
Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia
via: SeekingAlpha at 2018-11-27 08:00:00:000
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients … read more...
Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia
via: SeekingAlpha at 2018-11-27 08:00:00:000
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients … read more...
Agios Pharma's AG-881 shows potential treatment effect in early-stage brain/spinal cord cancer study
via: SeekingAlpha at 2018-11-16 08:17:51:000
Data on 52 patients showed a 73% discontinuation rate (n=38/52), principally due to cancer progression (n=29). Two dropped out due to adverse events. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Agios Pharma's AG-881 shows potential treatment effect in early-stage brain/spinal cord cancer study
via: SeekingAlpha at 2018-11-16 08:17:51:000
Data on 52 patients showed a 73% discontinuation rate (n=38/52), principally due to cancer progression (n=29). Two dropped out due to adverse events. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Agios Pharma's AG-881 shows potential treatment effect in early-stage brain/spinal cord cancer study
via: SeekingAlpha at 2018-11-16 08:17:51:000
Data on 52 patients showed a 73% discontinuation rate (n=38/52), principally due to cancer progression (n=29). Two dropped out due to adverse events. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Agios Pharma's AG-881 shows potential treatment effect in early-stage brain/spinal cord cancer study
via: SeekingAlpha at 2018-11-16 08:17:51:000
Data on 52 patients showed a 73% discontinuation rate (n=38/52), principally due to cancer progression (n=29). Two dropped out due to adverse events. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Agios Pharma's AG-881 shows potential treatment effect in early-stage brain/spinal cord cancer study
via: SeekingAlpha at 2018-11-16 08:17:51:000
Data on 52 patients showed a 73% discontinuation rate (n=38/52), principally due to cancer progression (n=29). Two dropped out due to adverse events. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals, Inc. (AGIO) CEO David Schenkein on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-01 14:47:10:000
Agios Pharmaceuticals, Inc. (AGIO) Q3 2018 Earnings Conference Call November 1, 2018 8:00 AM ET Executives Renee Leck - Associate Director, Investor Relations David Schenkein - Chief Executive Officer Chris Bowden - Chief Medical Officer Steve Hoerter - Chief Commercial Officer… read more...
Agios Pharmaceuticals, Inc. (AGIO) CEO David Schenkein on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-01 14:47:10:000
Agios Pharmaceuticals, Inc. (AGIO) Q3 2018 Earnings Conference Call November 1, 2018 8:00 AM ET Executives Renee Leck - Associate Director, Investor Relations David Schenkein - Chief Executive Officer Chris Bowden - Chief Medical Officer Steve Hoerter - Chief Commercial Officer… read more...
Agios Pharmaceuticals, Inc. (AGIO) CEO David Schenkein on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-01 14:47:10:000
Agios Pharmaceuticals, Inc. (AGIO) Q3 2018 Earnings Conference Call November 1, 2018 8:00 AM ET Executives Renee Leck - Associate Director, Investor Relations David Schenkein - Chief Executive Officer Chris Bowden - Chief Medical Officer Steve Hoerter - Chief Commercial Officer… read more...
Agios Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-11-01 08:24:25:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-11-01 08:24:25:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-11-01 08:24:25:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Agios Pharmaceuticals misses by $0.12, misses on revenue
via: SeekingAlpha at 2018-11-01 07:08:27:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q3 GAAP EPS of -$1.63 misses by $0.12 . Revenue of $15.2M (+33.8% Y/Y) misses by $3.92M . Press Release More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Agios Pharmaceuticals misses by $0.12, misses on revenue
via: SeekingAlpha at 2018-11-01 07:08:27:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q3 GAAP EPS of -$1.63 misses by $0.12 . Revenue of $15.2M (+33.8% Y/Y) misses by $3.92M . Press Release More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Agios Pharmaceuticals misses by $0.12, misses on revenue
via: SeekingAlpha at 2018-11-01 07:08:27:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q3 GAAP EPS of -$1.63 misses by $0.12 . Revenue of $15.2M (+33.8% Y/Y) misses by $3.92M . Press Release More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-10-31 17:30:40:000
AAON , AAWW , ABMD , AGIO , ALE , AMAG , AMCX , AME , AMRN , ARES , AROC , ARW , AVP , AYR , BCE , BID , BLL , BMCH , BSIG , CBRE , CCOI , CEIX , CHD , CHSP , CI , CJ , CNQ , CNSL , CWT , D , DM , DNOW , DWDP , EEX , EGRX , EPAM , EXC , EXLS , FLWS , F… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-09-25 08:31:34:000
Premier (NASDAQ: PINC ) initiated with Overweight rating and $50 (14% upside) price target at Barclays. More news on: Premier, Inc., Agios Pharmaceuticals, Inc., BeiGene, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-09-25 08:31:34:000
Premier (NASDAQ: PINC ) initiated with Overweight rating and $50 (14% upside) price target at Barclays. More news on: Premier, Inc., Agios Pharmaceuticals, Inc., BeiGene, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-09-25 08:31:34:000
Premier (NASDAQ: PINC ) initiated with Overweight rating and $50 (14% upside) price target at Barclays. More news on: Premier, Inc., Agios Pharmaceuticals, Inc., BeiGene, Healthcare stocks news, Stocks on the move, , Read more … read more...
For Investors Seeking Exposure To Biotech, BB Biotech AG Might Be An Interesting Alternative To Funds
via: SeekingAlpha at 2018-09-18 10:00:12:000
Biotech is a Growth Sector The biotech sector is largely growth driven. Especially, in the field of medicine lies huge growth potential for biotech. There is an ever-increasing demand for new and better treatments and medication for various diseases. Given the direction of demographic develo… read more...
For Investors Seeking Exposure To Biotech, BB Biotech AG Might Be An Interesting Alternative To Funds
via: SeekingAlpha at 2018-09-18 10:00:12:000
Biotech is a Growth Sector The biotech sector is largely growth driven. Especially, in the field of medicine lies huge growth potential for biotech. There is an ever-increasing demand for new and better treatments and medication for various diseases. Given the direction of demographic develo… read more...
For Investors Seeking Exposure To Biotech, BB Biotech AG Might Be An Interesting Alternative To Funds
via: SeekingAlpha at 2018-09-18 10:00:12:000
Biotech is a Growth Sector The biotech sector is largely growth driven. Especially, in the field of medicine lies huge growth potential for biotech. There is an ever-increasing demand for new and better treatments and medication for various diseases. Given the direction of demographic develo… read more...
Agios Pharma and Celgene terminate partnership developing AG-881
via: SeekingAlpha at 2018-09-05 07:39:51:000
Agios Pharmaceuticals (NASDAQ: AGIO ) and Celgene (NASDAQ: CELG ) have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881. More news on: Agios Pharmaceuticals, Inc., Cel… read more...
Agios Pharma and Celgene terminate partnership developing AG-881
via: SeekingAlpha at 2018-09-05 07:39:51:000
Agios Pharmaceuticals (NASDAQ: AGIO ) and Celgene (NASDAQ: CELG ) have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881. More news on: Agios Pharmaceuticals, Inc., Cel… read more...
Agios Pharma and Celgene terminate partnership developing AG-881
via: SeekingAlpha at 2018-09-05 07:39:51:000
Agios Pharmaceuticals (NASDAQ: AGIO ) and Celgene (NASDAQ: CELG ) have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881. More news on: Agios Pharmaceuticals, Inc., Cel… read more...
Agios Pharma names former Celgene exec Fouse as next CEO
via: SeekingAlpha at 2018-09-04 18:46:42:000
Agios Pharmaceuticals (NASDAQ: AGIO ) names former Celgene president and COO Jacqualyn Fouse as its next CEO , succeeding David Schenkein, who will become executive chairman effective next February. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-17 07:40:48:000
Noteworthy events during the week of August 19 - 25 for healthcare investors. More news on: Neurocrine Biosciences, Inc., Agios Pharmaceuticals, Inc., Mallinckrodt PLC, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-17 07:40:48:000
Noteworthy events during the week of August 19 - 25 for healthcare investors. More news on: Neurocrine Biosciences, Inc., Agios Pharmaceuticals, Inc., Mallinckrodt PLC, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-17 07:40:48:000
Noteworthy events during the week of August 19 - 25 for healthcare investors. More news on: Neurocrine Biosciences, Inc., Agios Pharmaceuticals, Inc., Mallinckrodt PLC, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-17 07:40:48:000
Noteworthy events during the week of August 19 - 25 for healthcare investors. More news on: Neurocrine Biosciences, Inc., Agios Pharmaceuticals, Inc., Mallinckrodt PLC, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-17 07:40:48:000
Noteworthy events during the week of August 19 - 25 for healthcare investors. More news on: Neurocrine Biosciences, Inc., Agios Pharmaceuticals, Inc., Mallinckrodt PLC, Healthcare stocks news, , Read more … read more...
Agios Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-02 14:12:22:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-02 14:12:22:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-02 14:12:22:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 13:47:14:000
Agios Pharmaceuticals, Inc. (AGIO) Q2 2018 Results Conference Call August 2, 2018 8:00 AM ET Executives Renee Leck Senior Manager-Investor Relations David Schenkein Chief Executive Officer Chris Bowden Chief Medical Officer Steve Hoerter Chie… read more...
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 13:47:14:000
Agios Pharmaceuticals, Inc. (AGIO) Q2 2018 Results Conference Call August 2, 2018 8:00 AM ET Executives Renee Leck Senior Manager-Investor Relations David Schenkein Chief Executive Officer Chris Bowden Chief Medical Officer Steve Hoerter Chie… read more...
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 13:47:14:000
Agios Pharmaceuticals, Inc. (AGIO) Q2 2018 Results Conference Call August 2, 2018 8:00 AM ET Executives Renee Leck Senior Manager-Investor Relations David Schenkein Chief Executive Officer Chris Bowden Chief Medical Officer Steve Hoerter Chie… read more...
Agios Pharmaceuticals beats by $0.36, beats on revenue
via: SeekingAlpha at 2018-08-02 07:03:53:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q2 EPS of -$1.19 beats by $0.36 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals beats by $0.36, beats on revenue
via: SeekingAlpha at 2018-08-02 07:03:53:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q2 EPS of -$1.19 beats by $0.36 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals beats by $0.36, beats on revenue
via: SeekingAlpha at 2018-08-02 07:03:53:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q2 EPS of -$1.19 beats by $0.36 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-08-01 17:30:46:000
AAON , AAWW , ABC , ACIW , ACOR , AET , AGIO , ALE , ALNY , AMAG , AMCX , APO , APRN , ARES , AROC , ARW , AVP , BCE , BDX , BLL , BSIG , CBM , CBRE , CBZ , CCOI , CDW , CEIX , CHD , CI , CJ , CLX , CNQ , CNSL , CNX , CNXM , COT , CRS , CTSH , DNOW , … read more...
Agios Pharma Notches Another FDA Approval Under Its Belt For Rare Cancer Treatment
via: SeekingAlpha at 2018-07-24 01:44:29:000
Recently, Agios Pharmaceuticals ( AGIO ) announced that the FDA had approved its drug TIBSOVO (developed as AG-120) for advanced acute myeloid leukemia (AML). This FDA approval comes roughly about a year after Agios received approval for another rare population for AML with a drug known as I… read more...
Agios Pharma Notches Another FDA Approval Under Its Belt For Rare Cancer Treatment
via: SeekingAlpha at 2018-07-24 01:44:29:000
Recently, Agios Pharmaceuticals ( AGIO ) announced that the FDA had approved its drug TIBSOVO (developed as AG-120) for advanced acute myeloid leukemia (AML). This FDA approval comes roughly about a year after Agios received approval for another rare population for AML with a drug known as I… read more...
Agios Pharma Notches Another FDA Approval Under Its Belt For Rare Cancer Treatment
via: SeekingAlpha at 2018-07-24 01:44:29:000
Recently, Agios Pharmaceuticals ( AGIO ) announced that the FDA had approved its drug TIBSOVO (developed as AG-120) for advanced acute myeloid leukemia (AML). This FDA approval comes roughly about a year after Agios received approval for another rare population for AML with a drug known as I… read more...
Agios Pharmaceuticals (AGIO) TIBSOVO FDA Approval - Slideshow
via: SeekingAlpha at 2018-07-23 12:49:50:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
3 Things In Biotech, July 23: Regulatory News Launches A New Franchise
via: SeekingAlpha at 2018-07-23 10:43:41:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Agios nabs their second approval Company: Agios Pharmaceuticals ( AGIO ) Therapy: Ivoside… read more...
Rounds Report: TransEnterix Caught A Break On A Down Day
via: SeekingAlpha at 2018-07-22 07:15:16:000
Weve really made the money out of high-quality businesses. In some cases, we bought the whole business. And in some cases, we just bought a big block of stock. But when you analyze what happened, the big moneys been made in the high-quality businesses. And most of the other pe… read more...
FDA OKs Agios Pharma's ivosidenib for certain type of AML
via: SeekingAlpha at 2018-07-20 11:13:43:000
The FDA approves Agios Pharmaceuticals' ( AGIO +0.6% ) TIBSOVO (ivosidenib) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Agios Pharmaceuticals, Inc., Healthcare sto… read more...
FDA OKs Agios Pharma's ivosidenib for certain type of AML
via: SeekingAlpha at 2018-07-20 11:13:43:000
The FDA approves Agios Pharmaceuticals' ( AGIO +0.6% ) TIBSOVO (ivosidenib) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Agios Pharmaceuticals, Inc., Healthcare sto… read more...
Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets
via: SeekingAlpha at 2018-07-09 08:00:00:000
The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...
Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets
via: SeekingAlpha at 2018-07-09 08:00:00:000
The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...
Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets
via: SeekingAlpha at 2018-07-09 08:00:00:000
The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
via: SeekingAlpha at 2018-07-01 07:14:07:000
Deals and Financings CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios (AGIO), a Boston area pharma, in a deal worth up to $424 million (see story ). CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia ((AML)) and c… read more...
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
via: SeekingAlpha at 2018-07-01 07:14:07:000
Deals and Financings CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios (AGIO), a Boston area pharma, in a deal worth up to $424 million (see story ). CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia ((AML)) and c… read more...
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
via: SeekingAlpha at 2018-07-01 07:14:07:000
Deals and Financings CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios (AGIO), a Boston area pharma, in a deal worth up to $424 million (see story ). CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia ((AML)) and c… read more...
A Short Case For A Longer Term!
via: SeekingAlpha at 2018-06-20 11:10:51:000
New York Stock Exchange Staying The Course, Including Drawdowns, Within A Bull Market The stock market is recording new all-time highs. The market has been led by the Russell 2000 ( IWM ) small cap index, which achieved the milestone in May, after a 3-month period of weakness for stocks…. read more...
A Short Case For A Longer Term!
via: SeekingAlpha at 2018-06-20 11:10:51:000
New York Stock Exchange Staying The Course, Including Drawdowns, Within A Bull Market The stock market is recording new all-time highs. The market has been led by the Russell 2000 ( IWM ) small cap index, which achieved the milestone in May, after a 3-month period of weakness for stocks…. read more...
A Short Case For A Longer Term!
via: SeekingAlpha at 2018-06-20 11:10:51:000
New York Stock Exchange Staying The Course, Including Drawdowns, Within A Bull Market The stock market is recording new all-time highs. The market has been led by the Russell 2000 ( IWM ) small cap index, which achieved the milestone in May, after a 3-month period of weakness for stocks…. read more...
Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3
via: SeekingAlpha at 2018-06-20 08:00:00:000
Analysis Focus: TGTX TG Therapeutics ( TGTX ) announced preliminary data from the Phase 2 clinical trial of its lead candidate umbralisib (TGR-1202) in patients with relapsed/refractory chronic lymphocytic leukemia or r/r CLL, who were intolerant to prior BTK or PI3K therapy. The data that… read more...
Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3
via: SeekingAlpha at 2018-06-20 08:00:00:000
Analysis Focus: TGTX TG Therapeutics ( TGTX ) announced preliminary data from the Phase 2 clinical trial of its lead candidate umbralisib (TGR-1202) in patients with relapsed/refractory chronic lymphocytic leukemia or r/r CLL, who were intolerant to prior BTK or PI3K therapy. The data that… read more...
Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3
via: SeekingAlpha at 2018-06-20 08:00:00:000
Analysis Focus: TGTX TG Therapeutics ( TGTX ) announced preliminary data from the Phase 2 clinical trial of its lead candidate umbralisib (TGR-1202) in patients with relapsed/refractory chronic lymphocytic leukemia or r/r CLL, who were intolerant to prior BTK or PI3K therapy. The data that… read more...
Agios launches late-stage study of AG-348 in PKD; shares up 2%
via: SeekingAlpha at 2018-06-18 13:36:41:000
Agios Pharmaceuticals ( AGIO +1.7% ) initiates a Phase 3 clinical trial, ACTIVATE , evaluating PKR enzyme activator AG-348 in 80 adults with pyruvate kinase deficiency (PKD) who do not receive regular blood transfusions. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks new… read more...
Agios launches late-stage study of AG-348 in PKD; shares up 2%
via: SeekingAlpha at 2018-06-18 13:36:41:000
Agios Pharmaceuticals ( AGIO +1.7% ) initiates a Phase 3 clinical trial, ACTIVATE , evaluating PKR enzyme activator AG-348 in 80 adults with pyruvate kinase deficiency (PKD) who do not receive regular blood transfusions. More news on: Agios Pharmaceuticals, Inc., Healthcare stocks new… read more...
ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed
via: SeekingAlpha at 2018-06-13 09:16:27:000
Last week, two major meetings for biotechnology and pharmaceutical companies occurred at the same time. The ASCO annual meeting, the biggest oncology event in North America, was held from June 1 to 5 in Chicago. The BIO International Convention 2018, hosted by the Biotechnology Innovation Org… read more...
ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed
via: SeekingAlpha at 2018-06-13 09:16:27:000
Last week, two major meetings for biotechnology and pharmaceutical companies occurred at the same time. The ASCO annual meeting, the biggest oncology event in North America, was held from June 1 to 5 in Chicago. The BIO International Convention 2018, hosted by the Biotechnology Innovation Org… read more...
ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed
via: SeekingAlpha at 2018-06-13 09:16:27:000
Last week, two major meetings for biotechnology and pharmaceutical companies occurred at the same time. The ASCO annual meeting, the biggest oncology event in North America, was held from June 1 to 5 in Chicago. The BIO International Convention 2018, hosted by the Biotechnology Innovation Org… read more...
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher
via: SeekingAlpha at 2018-05-31 16:08:11:000
Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher
via: SeekingAlpha at 2018-05-31 16:08:11:000
Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher
via: SeekingAlpha at 2018-05-31 16:08:11:000
Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-31 09:09:43:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Overweight rating and $125 (38% upside) price target at Piper Jaffray. More news on: Agios Pharmaceuticals, Inc., Celyad, Edwards Lifesciences Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-31 09:09:43:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Overweight rating and $125 (38% upside) price target at Piper Jaffray. More news on: Agios Pharmaceuticals, Inc., Celyad, Edwards Lifesciences Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-31 09:09:43:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Overweight rating and $125 (38% upside) price target at Piper Jaffray. More news on: Agios Pharmaceuticals, Inc., Celyad, Edwards Lifesciences Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-23 08:34:36:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Buy rating and $117 (36% upside) price target at Citigroup. More news on: Agios Pharmaceuticals, Inc., HealthEquity, Vanda Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-23 08:34:36:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Buy rating and $117 (36% upside) price target at Citigroup. More news on: Agios Pharmaceuticals, Inc., HealthEquity, Vanda Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-23 08:34:36:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Buy rating and $117 (36% upside) price target at Citigroup. More news on: Agios Pharmaceuticals, Inc., HealthEquity, Vanda Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-23 08:34:36:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Buy rating and $117 (36% upside) price target at Citigroup. More news on: Agios Pharmaceuticals, Inc., HealthEquity, Vanda Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-23 08:34:36:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Buy rating and $117 (36% upside) price target at Citigroup. More news on: Agios Pharmaceuticals, Inc., HealthEquity, Vanda Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-23 08:34:36:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Buy rating and $117 (36% upside) price target at Citigroup. More news on: Agios Pharmaceuticals, Inc., HealthEquity, Vanda Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-23 08:34:36:000
Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Buy rating and $117 (36% upside) price target at Citigroup. More news on: Agios Pharmaceuticals, Inc., HealthEquity, Vanda Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
via: SeekingAlpha at 2018-05-19 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
Biotechs Emerge Unscathed And Ready To Go!
via: SeekingAlpha at 2018-05-15 08:28:41:000
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...
Biotechs Emerge Unscathed And Ready To Go!
via: SeekingAlpha at 2018-05-15 08:28:41:000
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...
Biotechs Emerge Unscathed And Ready To Go!
via: SeekingAlpha at 2018-05-15 08:28:41:000
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...
Biotechs Emerge Unscathed And Ready To Go!
via: SeekingAlpha at 2018-05-15 08:28:41:000
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...
Biotechs Emerge Unscathed And Ready To Go!
via: SeekingAlpha at 2018-05-15 08:28:41:000
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...
Biotechs Emerge Unscathed And Ready To Go!
via: SeekingAlpha at 2018-05-15 08:28:41:000
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...
A Fresh Look At Celgene After Q1 And New Info On Ozanimod
via: SeekingAlpha at 2018-05-08 05:10:11:000
Introduction - A perplexing stock This article covers issues about Celgene (CELG) that are on my mind, some of which may be on the minds of various investors, large and small. This stock was one of my few significant investment disappointments last year in what was otherwise a very fine year… read more...
A Fresh Look At Celgene After Q1 And New Info On Ozanimod
via: SeekingAlpha at 2018-05-08 05:10:11:000
Introduction - A perplexing stock This article covers issues about Celgene (CELG) that are on my mind, some of which may be on the minds of various investors, large and small. This stock was one of my few significant investment disappointments last year in what was otherwise a very fine year… read more...
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Investor Day 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-06 00:49:03:000
Agios Pharmaceuticals, Inc. (AGIO) Investor Day 2018 Results Earnings Conference Call May 04, 2018, 08:00 AM ET Executives David Schenkein - CEO Scott Biller - Chief Scientific Officer Kevin Marks - Senior Director, Head of Cancer Biology Darrin Miles - Vice President, IDH Prog… read more...
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Investor Day 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-06 00:49:03:000
Agios Pharmaceuticals, Inc. (AGIO) Investor Day 2018 Results Earnings Conference Call May 04, 2018, 08:00 AM ET Executives David Schenkein - CEO Scott Biller - Chief Scientific Officer Kevin Marks - Senior Director, Head of Cancer Biology Darrin Miles - Vice President, IDH Prog… read more...
Agios Pharmaceuticals (AGIO) Investor Presentation - Slideshow
via: SeekingAlpha at 2018-05-04 14:07:08:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals (AGIO) Investor Presentation - Slideshow
via: SeekingAlpha at 2018-05-04 14:07:08:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals EPS in-line, misses on revenue
via: SeekingAlpha at 2018-05-04 07:05:10:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q1 EPS of -$1.63 in-line. More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals EPS in-line, misses on revenue
via: SeekingAlpha at 2018-05-04 07:05:10:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q1 EPS of -$1.63 in-line. More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Notable earnings before Friday's open
via: SeekingAlpha at 2018-05-03 17:30:43:000
ABR , ACAD , AGIO , AON , ASIX , AXL , BABA , BCC , BPL , CBOE , CELG , CIO , CNP , DOC , ESNT , GEL , GLOG , GOGO , HMSY , IDXX , IMGN , IONS , ITT , LCII , LNG , LPNT , NJR , NWL , ROCK , RUTH , STWD , TRTN , TWI , VER , VIRT , VST , WPC For Seekin… read more...
Notable earnings before Friday's open
via: SeekingAlpha at 2018-05-03 17:30:43:000
ABR , ACAD , AGIO , AON , ASIX , AXL , BABA , BCC , BPL , CBOE , CELG , CIO , CNP , DOC , ESNT , GEL , GLOG , GOGO , HMSY , IDXX , IMGN , IONS , ITT , LCII , LNG , LPNT , NJR , NWL , ROCK , RUTH , STWD , TRTN , TWI , VER , VIRT , VST , WPC For Seekin… read more...
ASLAN Pharmaceuticals Updates U.S. IPO Plans
via: SeekingAlpha at 2018-04-18 17:49:43:000
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o… read more...
ASLAN Pharmaceuticals Updates U.S. IPO Plans
via: SeekingAlpha at 2018-04-18 17:49:43:000
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o… read more...
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned
via: SeekingAlpha at 2018-04-13 09:17:12:000
Biotech Pulse When the market experiences rain, biotechs experience a thunderstorm. That's how volatility relates to biotechnology - one of the most promising and nerve-wracking industries in the stock market. As the market succumbed last week to the drumbeat of a tariff war, volatility sp… read more...
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned
via: SeekingAlpha at 2018-04-13 09:17:12:000
Biotech Pulse When the market experiences rain, biotechs experience a thunderstorm. That's how volatility relates to biotechnology - one of the most promising and nerve-wracking industries in the stock market. As the market succumbed last week to the drumbeat of a tariff war, volatility sp… read more...
Agios and Jounce spike on potential Celgene interest
via: SeekingAlpha at 2018-04-09 10:30:18:000
Agios Pharmaceuticals ( AGIO +8.5% ) and Jounce Therapeutics ( JNCE +11.1% ) perk up on the heels of a Financial Times article that they would be attractive takeover targets for deal-hungry Celgene ( CELG +1.1% ). More news on: Agios Pharmaceuticals, Inc., Jounce Therapeutics, Celg… read more...
Agios and Jounce spike on potential Celgene interest
via: SeekingAlpha at 2018-04-09 10:30:18:000
Agios Pharmaceuticals ( AGIO +8.5% ) and Jounce Therapeutics ( JNCE +11.1% ) perk up on the heels of a Financial Times article that they would be attractive takeover targets for deal-hungry Celgene ( CELG +1.1% ). More news on: Agios Pharmaceuticals, Inc., Jounce Therapeutics, Celg… read more...
ASLAN Pharmaceuticals Files For $86 Million U.S. IPO
via: SeekingAlpha at 2018-04-06 13:28:03:000
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to sell ADSs of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an F-1 registration statement . The firm is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents a… read more...
ASLAN Pharmaceuticals Files For $86 Million U.S. IPO
via: SeekingAlpha at 2018-04-06 13:28:03:000
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to sell ADSs of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an F-1 registration statement . The firm is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents a… read more...
Celgene's Otezla-Colitis Story; Implications For Other Biotechs
via: SeekingAlpha at 2018-02-16 16:51:36:000
Introduction Celgene ( CELG ) is back to 2014 levels, closing Friday at $96.14. It first reached this price in August 2014. Yet I just want to sit with it. Even with CELG down to safer valuations, among non-dividend-paying biotechs, I currently prefer Regeneron ( REGN ) at $333 and Vertex … read more...
Celgene's Otezla-Colitis Story; Implications For Other Biotechs
via: SeekingAlpha at 2018-02-16 16:51:36:000
Introduction Celgene ( CELG ) is back to 2014 levels, closing Friday at $96.14. It first reached this price in August 2014. Yet I just want to sit with it. Even with CELG down to safer valuations, among non-dividend-paying biotechs, I currently prefer Regeneron ( REGN ) at $333 and Vertex … read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
FDA accepts Agios Pharma's marketing application for ivosidenib for AML
via: SeekingAlpha at 2018-02-15 12:19:59:000
The FDA accepts under Priority Review Agios Pharmaceuticals' ( AGIO -0.1% ) New Drug Application (NDA) seeking approval for ivosidenib for the treatment of isocitrate dehydrogenase 1 (IDH1) mutation-positive relapsed/refractory acute myeloid leukemia (AML). The agency's action date is Au… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-14 19:37:06:000
Agios Pharmaceuticals, Inc. (AGIO) Q4 2017 Results Conference Call February 14, 2018 08:00 AM ET Executives Kendra Adams - Senior Director, IR and Public Relations Dr. David Schenkein - CEO Dr. Chris Bowden - CMO Andrew Hirsch - CFO Dr. Scott Biller - Chief Scientific Officer… read more...
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-14 15:11:38:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-14 15:11:38:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-14 15:11:38:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-14 15:11:38:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-14 15:11:38:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-14 15:11:38:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-14 15:11:38:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Agios Pharmaceuticals misses by $0.15, misses on revenue
via: SeekingAlpha at 2018-02-14 07:03:55:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 EPS of -$1.81 misses by $0.15 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals misses by $0.15, misses on revenue
via: SeekingAlpha at 2018-02-14 07:03:55:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 EPS of -$1.81 misses by $0.15 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals misses by $0.15, misses on revenue
via: SeekingAlpha at 2018-02-14 07:03:55:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 EPS of -$1.81 misses by $0.15 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals misses by $0.15, misses on revenue
via: SeekingAlpha at 2018-02-14 07:03:55:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 EPS of -$1.81 misses by $0.15 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals misses by $0.15, misses on revenue
via: SeekingAlpha at 2018-02-14 07:03:55:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 EPS of -$1.81 misses by $0.15 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals misses by $0.15, misses on revenue
via: SeekingAlpha at 2018-02-14 07:03:55:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 EPS of -$1.81 misses by $0.15 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Agios Pharmaceuticals misses by $0.15, misses on revenue
via: SeekingAlpha at 2018-02-14 07:03:55:000
Agios Pharmaceuticals (NASDAQ: AGIO ): Q4 EPS of -$1.81 misses by $0.15 . More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-02-13 17:30:16:000
ACCO , AER , AGIO , ALKS , BG , CIGI , CIM , CMS , CRTO , CYRN , DNOW , DPS , FLIR , FUN , GEO , GRPN , HLT , ICL , ICPT , IPG , IQV , LAD , LECO , MZOR , OMI , ORBK , PLAB , SABR , SHPG , SODA , STNG , SUM , TAP , TCX , TECK , WIX , WYN For Seeking … read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-02-13 17:30:16:000
ACCO , AER , AGIO , ALKS , BG , CIGI , CIM , CMS , CRTO , CYRN , DNOW , DPS , FLIR , FUN , GEO , GRPN , HLT , ICL , ICPT , IPG , IQV , LAD , LECO , MZOR , OMI , ORBK , PLAB , SABR , SHPG , SODA , STNG , SUM , TAP , TCX , TECK , WIX , WYN For Seeking … read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-02-13 17:30:16:000
ACCO , AER , AGIO , ALKS , BG , CIGI , CIM , CMS , CRTO , CYRN , DNOW , DPS , FLIR , FUN , GEO , GRPN , HLT , ICL , ICPT , IPG , IQV , LAD , LECO , MZOR , OMI , ORBK , PLAB , SABR , SHPG , SODA , STNG , SUM , TAP , TCX , TECK , WIX , WYN For Seeking … read more...
Biotech Developer Stock Price Risks & Returns: An Understanding Today
via: SeekingAlpha at 2018-01-30 13:41:33:000
This is not an analysis of the economic, competitive or political fundamentals of this industry group. Instead it is a detailed comparison of the coming near-term price-change prospects for the stocks, based on the up-to-the-day evaluations of experienced and well-informed anal… read more...
Biotech Developer Stock Price Risks & Returns: An Understanding Today
via: SeekingAlpha at 2018-01-30 13:41:33:000
This is not an analysis of the economic, competitive or political fundamentals of this industry group. Instead it is a detailed comparison of the coming near-term price-change prospects for the stocks, based on the up-to-the-day evaluations of experienced and well-informed anal… read more...
Biotech Developer Stock Price Risks & Returns: An Understanding Today
via: SeekingAlpha at 2018-01-30 13:41:33:000
This is not an analysis of the economic, competitive or political fundamentals of this industry group. Instead it is a detailed comparison of the coming near-term price-change prospects for the stocks, based on the up-to-the-day evaluations of experienced and well-informed anal… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering
via: SeekingAlpha at 2018-01-19 08:00:00:000
Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...
Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering
via: SeekingAlpha at 2018-01-19 08:00:00:000
Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...
Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering
via: SeekingAlpha at 2018-01-19 08:00:00:000
Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...
Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering
via: SeekingAlpha at 2018-01-19 08:00:00:000
Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...
Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering
via: SeekingAlpha at 2018-01-19 08:00:00:000
Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...
3 Things In Biotech You Should Learn Today: January 10, 2018
via: SeekingAlpha at 2018-01-11 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. And I announced this yesterday via blog post, but I wanted to let you know officially once ag… read more...
3 Things In Biotech You Should Learn Today: January 10, 2018
via: SeekingAlpha at 2018-01-11 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. And I announced this yesterday via blog post, but I wanted to let you know officially once ag… read more...
3 Things In Biotech You Should Learn Today: January 10, 2018
via: SeekingAlpha at 2018-01-11 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. And I announced this yesterday via blog post, but I wanted to let you know officially once ag… read more...
3 Things In Biotech You Should Learn Today: January 10, 2018
via: SeekingAlpha at 2018-01-11 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. And I announced this yesterday via blog post, but I wanted to let you know officially once ag… read more...
3 Things In Biotech You Should Learn Today: January 10, 2018
via: SeekingAlpha at 2018-01-11 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. And I announced this yesterday via blog post, but I wanted to let you know officially once ag… read more...
Agios Gears Up Pipeline To Create Future Value
via: SeekingAlpha at 2018-01-10 11:20:28:000
Agios ( AGIO ) became a commercial stage biotech pharmaceutical company in August 2017 when the FDA approved Idhifa for AML (acute myeloid leukemia) with certain specific biomarkers. Celgene ( CELG ) owns Idhifa, with Agios to receive royalties. Agios has other collaborations with Celgene, p… read more...
Agios Gears Up Pipeline To Create Future Value
via: SeekingAlpha at 2018-01-10 11:20:28:000
Agios ( AGIO ) became a commercial stage biotech pharmaceutical company in August 2017 when the FDA approved Idhifa for AML (acute myeloid leukemia) with certain specific biomarkers. Celgene ( CELG ) owns Idhifa, with Agios to receive royalties. Agios has other collaborations with Celgene, p… read more...
Agios Gears Up Pipeline To Create Future Value
via: SeekingAlpha at 2018-01-10 11:20:28:000
Agios ( AGIO ) became a commercial stage biotech pharmaceutical company in August 2017 when the FDA approved Idhifa for AML (acute myeloid leukemia) with certain specific biomarkers. Celgene ( CELG ) owns Idhifa, with Agios to receive royalties. Agios has other collaborations with Celgene, p… read more...
Agios Gears Up Pipeline To Create Future Value
via: SeekingAlpha at 2018-01-10 11:20:28:000
Agios ( AGIO ) became a commercial stage biotech pharmaceutical company in August 2017 when the FDA approved Idhifa for AML (acute myeloid leukemia) with certain specific biomarkers. Celgene ( CELG ) owns Idhifa, with Agios to receive royalties. Agios has other collaborations with Celgene, p… read more...
Agios Gears Up Pipeline To Create Future Value
via: SeekingAlpha at 2018-01-10 11:20:28:000
Agios ( AGIO ) became a commercial stage biotech pharmaceutical company in August 2017 when the FDA approved Idhifa for AML (acute myeloid leukemia) with certain specific biomarkers. Celgene ( CELG ) owns Idhifa, with Agios to receive royalties. Agios has other collaborations with Celgene, p… read more...
Agios Pharmaceuticals (AGIO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-01-09 13:35:35:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals (AGIO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-01-09 13:35:35:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals (AGIO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-01-09 13:35:35:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals (AGIO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-01-09 13:35:35:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Agios Pharmaceuticals (AGIO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-01-09 13:35:35:000
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
via: Business Wire at 2018-01-08 14:02:00:000
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. (Agios or the Company) (NASDAQ:AGIO) into potential breaches of fiduciary duty by the Companys Board of Directors (t… read more...
Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
via: Business Wire at 2018-01-08 14:02:00:000
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. (Agios or the Company) (NASDAQ:AGIO) into potential breaches of fiduciary duty by the Companys Board of Directors (t… read more...
Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
via: Business Wire at 2018-01-08 14:02:00:000
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. (Agios or the Company) (NASDAQ:AGIO) into potential breaches of fiduciary duty by the Companys Board of Directors (t… read more...
Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
via: Business Wire at 2018-01-08 14:02:00:000
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. (Agios or the Company) (NASDAQ:AGIO) into potential breaches of fiduciary duty by the Companys Board of Directors (t… read more...
Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
via: Business Wire at 2018-01-08 14:02:00:000
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. (Agios or the Company) (NASDAQ:AGIO) into potential breaches of fiduciary duty by the Companys Board of Directors (t… read more...
Goldman bullish on biopharma in 2018
via: SeekingAlpha at 2018-01-05 09:48:24:000
In a note, Goldman Sachs analyst Salveen Richter says M&A activity in the biopharma space should pick up this year. Likely buyers include Celgene ( CELG -1% ), Pfizer ( PFE -0.2% ), Merck ( MRK +0.2% ) and J&J ( JNJ ), AbbVie ( ABBV -0.5% ), Amgen ( AMGN ), AstraZeneca ( AZN … read more...
Goldman bullish on biopharma in 2018
via: SeekingAlpha at 2018-01-05 09:48:24:000
In a note, Goldman Sachs analyst Salveen Richter says M&A activity in the biopharma space should pick up this year. Likely buyers include Celgene ( CELG -1% ), Pfizer ( PFE -0.2% ), Merck ( MRK +0.2% ) and J&J ( JNJ ), AbbVie ( ABBV -0.5% ), Amgen ( AMGN ), AstraZeneca ( AZN … read more...
Goldman bullish on biopharma in 2018
via: SeekingAlpha at 2018-01-05 09:48:24:000
In a note, Goldman Sachs analyst Salveen Richter says M&A activity in the biopharma space should pick up this year. Likely buyers include Celgene ( CELG -1% ), Pfizer ( PFE -0.2% ), Merck ( MRK +0.2% ) and J&J ( JNJ ), AbbVie ( ABBV -0.5% ), Amgen ( AMGN ), AstraZeneca ( AZN … read more...
Goldman bullish on biopharma in 2018
via: SeekingAlpha at 2018-01-05 09:48:24:000
In a note, Goldman Sachs analyst Salveen Richter says M&A activity in the biopharma space should pick up this year. Likely buyers include Celgene ( CELG -1% ), Pfizer ( PFE -0.2% ), Merck ( MRK +0.2% ) and J&J ( JNJ ), AbbVie ( ABBV -0.5% ), Amgen ( AMGN ), AstraZeneca ( AZN … read more...
Goldman bullish on biopharma in 2018
via: SeekingAlpha at 2018-01-05 09:48:24:000
In a note, Goldman Sachs analyst Salveen Richter says M&A activity in the biopharma space should pick up this year. Likely buyers include Celgene ( CELG -1% ), Pfizer ( PFE -0.2% ), Merck ( MRK +0.2% ) and J&J ( JNJ ), AbbVie ( ABBV -0.5% ), Amgen ( AMGN ), AstraZeneca ( AZN … read more...
Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results
via: SeekingAlpha at 2018-01-03 01:25:29:000
Analysis of top Seeking Alpha coverage: Achaogen Today we will discuss the latest update from Achaogen ( AKAO ). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market…. read more...
Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results
via: SeekingAlpha at 2018-01-03 01:25:29:000
Analysis of top Seeking Alpha coverage: Achaogen Today we will discuss the latest update from Achaogen ( AKAO ). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market…. read more...
Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results
via: SeekingAlpha at 2018-01-03 01:25:29:000
Analysis of top Seeking Alpha coverage: Achaogen Today we will discuss the latest update from Achaogen ( AKAO ). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market…. read more...
Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results
via: SeekingAlpha at 2018-01-03 01:25:29:000
Analysis of top Seeking Alpha coverage: Achaogen Today we will discuss the latest update from Achaogen ( AKAO ). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market…. read more...
Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results
via: SeekingAlpha at 2018-01-03 01:25:29:000
Analysis of top Seeking Alpha coverage: Achaogen Today we will discuss the latest update from Achaogen ( AKAO ). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market…. read more...
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
via: SeekingAlpha at 2017-12-28 01:42:08:000
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu… read more...
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
via: SeekingAlpha at 2017-12-28 01:42:08:000
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu… read more...
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
via: SeekingAlpha at 2017-12-28 01:42:08:000
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu… read more...
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
via: SeekingAlpha at 2017-12-28 01:42:08:000
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu… read more...
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
via: SeekingAlpha at 2017-12-28 01:42:08:000
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu… read more...
Agios submits NDA for Ivosidenib for the treatment of relapsed/refractory AML and an IDH1 mutation
via: SeekingAlpha at 2017-12-26 08:37:13:000
Agios Pharmaceuticals (NASDAQ: AGIO ) submits a New Drug Application (NDA) to the FDA for ivosidenib (AG-120), an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Ag… read more...
Agios submits NDA for Ivosidenib for the treatment of relapsed/refractory AML and an IDH1 mutation
via: SeekingAlpha at 2017-12-26 08:37:13:000
Agios Pharmaceuticals (NASDAQ: AGIO ) submits a New Drug Application (NDA) to the FDA for ivosidenib (AG-120), an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Ag… read more...
Agios submits NDA for Ivosidenib for the treatment of relapsed/refractory AML and an IDH1 mutation
via: SeekingAlpha at 2017-12-26 08:37:13:000
Agios Pharmaceuticals (NASDAQ: AGIO ) submits a New Drug Application (NDA) to the FDA for ivosidenib (AG-120), an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Ag… read more...
Agios submits NDA for Ivosidenib for the treatment of relapsed/refractory AML and an IDH1 mutation
via: SeekingAlpha at 2017-12-26 08:37:13:000
Agios Pharmaceuticals (NASDAQ: AGIO ) submits a New Drug Application (NDA) to the FDA for ivosidenib (AG-120), an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Ag… read more...
Agios submits NDA for Ivosidenib for the treatment of relapsed/refractory AML and an IDH1 mutation
via: SeekingAlpha at 2017-12-26 08:37:13:000
Agios Pharmaceuticals (NASDAQ: AGIO ) submits a New Drug Application (NDA) to the FDA for ivosidenib (AG-120), an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Ag… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|